Syndax Pharmaceuticals Inc
SNDX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$13.40
KIRA · Stoqly’s AI analyst, in plain words
- Syndax Pharmaceuticals Inc had $172M of revenue in fiscal 2025, up 627.8% on the year before. Over five years, revenue changed +157.7% a year on average.
- Its operating margin was −158.4%, up 1,276.0 pts: of every 100 in sales, about −158 is left after running the business.
- Syndax Pharmaceuticals Inc lost $285M in fiscal 2025.
- Free cash flow was −$323M in fiscal 2025, −187.5% of revenue.
- Syndax Pharmaceuticals Inc owes $300M more than it holds in cash.
Market cap
$1.2B
P/E
—
Revenue
$172M
Net income
−$285M
Free cash flow
−$323M
Operating margin
−158.4%
Syndax Pharmaceuticals Inc in 30 seconds · fiscal 2025
Are sales growing?
+627.8%
Yes. Sales grew 627.8% last year.
Does it make a profit?
−165.6%
No. It lost money last year.
Does profit turn into cash?
−187.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Syndax Pharmaceuticals Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Syndax Pharmaceuticals Inc
- CIK
- 0001395937
Syndax Pharmaceuticals Inc · SNDX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $140M | $0.0M | $0.0M | $23.7M | $172M |
| Revenue growth | 9,109.6% | −100.0% | — | — | 627.8% |
| Operating margin | 18.8% | — | — | −1,434.4% | −158.4% |
| Net income | $24.9M | −$149M | −$209M | −$319M | −$285M |
| Net margin | 17.8% | — | — | −1,346.1% | −165.6% |
| Diluted EPS | $0.46 | −$2.46 | −$2.98 | −$3.72 | −$3.29 |
| Cash | |||||
| Cash from operations | $29.1M | −$134M | −$161M | −$275M | −$323M |
| Capital expenditure | $0.1M | $0.0M | $0.0M | $0.0M | $0.2M |
| Free cash flow | $29.0M | −$134M | −$161M | −$275M | −$323M |
| FCF margin | 20.8% | — | — | −1,160.9% | −187.5% |
| Share count change | 29.8% | 13.3% | 15.8% | 21.7% | 1.2% |
| Debt and strength | |||||
| Cash and short-term investments | $440M | $476M | $571M | $573M | $394M |
| Debt incl. finance leases | — | — | $0.0M | $682M | $694M |
| Shareholders' equity | $408M | $467M | $554M | $288M | $64.6M |
| Current ratio | 21.7x | 16.9x | 10.0x | 5.8x | 4.4x |
| Interest coverage | 13.8x | −48.4x | −1,105.5x | — | −45,514.0x |
| Returns and quality | |||||
| Return on capital | — | — | — | −67.6% | −59.2% |
| Return on equity | 7.5% | −34.1% | −41.0% | −75.7% | −161.8% |
| Return on tangible equity | 6.1% | −31.9% | −37.8% | −110.6% | −441.6% |
| Piotroski F-score | 6 | 1 | 1 | 2 | 1 |
| Altman Z'' | 13.1 | 16.0 | 8.2 | −3.4 | −7.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$2.7M
3 insiders
Of sales under plans
72%
$2.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Syndax Pharmaceuticals Inc · SNDX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $13.40 a share, the company is worth $1.2B.
Source: SEC EDGAR XBRL filings (CIK 0001395937). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.